Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients

Athanasios B.T. Fassas; Trey Spencer; Raman Desikan; Maurizio Zangari; Elias Anaissie; Bart Barlogie; Guido Tricot

doi:10.1046/j.1365-2141.2002.03772.x

Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients

Athanasios B.T. Fassas, Trey Spencer, Raman Desikan, Maurizio Zangari, Elias Anaissie, Bart Barlogie, Guido Tricot

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

High-dose treatment (HDT) with autologous stem cell transplant (ASCT) is superior to conventional chemotherapy in multiple myeloma. However, relapses eventually occur, especially in the presence of unfavourable cytogenetic abnormalities, high β-2 microglobulin levels prior to transplant and extensive prior treatment. Cytotoxic consolidation chemotherapy, following tandem transplants (TT), was given to 75 myeloma patients with at least one poor prognostic factor. When their outcome was compared with that of 75 matched controls who received dexamethasone ± interferon post TT, no event-free or overall survival advantage was observed. Other approaches may be required to improve survival in multiple myeloma.

Original language	English
Pages (from-to)	164-168
Number of pages	5
Journal	British Journal of Haematology
Volume	119
Issue number	1
DOIs	https://doi.org/10.1046/j.1365-2141.2002.03772.x
State	Published - 2002
Externally published	Yes

Keywords

Multiple myeloma
Post-transplant chemotherapy

Access to Document

10.1046/j.1365-2141.2002.03772.x

Cite this

@article{bb769b00530e4c08a025dace3601a56c,

title = "Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients",

abstract = "High-dose treatment (HDT) with autologous stem cell transplant (ASCT) is superior to conventional chemotherapy in multiple myeloma. However, relapses eventually occur, especially in the presence of unfavourable cytogenetic abnormalities, high β-2 microglobulin levels prior to transplant and extensive prior treatment. Cytotoxic consolidation chemotherapy, following tandem transplants (TT), was given to 75 myeloma patients with at least one poor prognostic factor. When their outcome was compared with that of 75 matched controls who received dexamethasone ± interferon post TT, no event-free or overall survival advantage was observed. Other approaches may be required to improve survival in multiple myeloma.",

keywords = "Multiple myeloma, Post-transplant chemotherapy",

author = "Fassas, {Athanasios B.T.} and Trey Spencer and Raman Desikan and Maurizio Zangari and Elias Anaissie and Bart Barlogie and Guido Tricot",

year = "2002",

doi = "10.1046/j.1365-2141.2002.03772.x",

language = "English",

volume = "119",

pages = "164--168",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients

AU - Fassas, Athanasios B.T.

AU - Spencer, Trey

AU - Desikan, Raman

AU - Zangari, Maurizio

AU - Anaissie, Elias

AU - Barlogie, Bart

AU - Tricot, Guido

PY - 2002

Y1 - 2002

N2 - High-dose treatment (HDT) with autologous stem cell transplant (ASCT) is superior to conventional chemotherapy in multiple myeloma. However, relapses eventually occur, especially in the presence of unfavourable cytogenetic abnormalities, high β-2 microglobulin levels prior to transplant and extensive prior treatment. Cytotoxic consolidation chemotherapy, following tandem transplants (TT), was given to 75 myeloma patients with at least one poor prognostic factor. When their outcome was compared with that of 75 matched controls who received dexamethasone ± interferon post TT, no event-free or overall survival advantage was observed. Other approaches may be required to improve survival in multiple myeloma.

AB - High-dose treatment (HDT) with autologous stem cell transplant (ASCT) is superior to conventional chemotherapy in multiple myeloma. However, relapses eventually occur, especially in the presence of unfavourable cytogenetic abnormalities, high β-2 microglobulin levels prior to transplant and extensive prior treatment. Cytotoxic consolidation chemotherapy, following tandem transplants (TT), was given to 75 myeloma patients with at least one poor prognostic factor. When their outcome was compared with that of 75 matched controls who received dexamethasone ± interferon post TT, no event-free or overall survival advantage was observed. Other approaches may be required to improve survival in multiple myeloma.

KW - Multiple myeloma

KW - Post-transplant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036402340&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03772.x

DO - 10.1046/j.1365-2141.2002.03772.x

M3 - Article

C2 - 12358921

AN - SCOPUS:0036402340

SN - 0007-1048

VL - 119

SP - 164

EP - 168

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this